Each year, strokes affect 15 million people worldwide. In the United States, stroke is the leading cause of long-term disability and the fourth-leading cause of death. Each year, strokes cost the U.S. healthcare system in excess of $73 billion. Approximately 90% of all strokes are caused by a blood clot, for which there is still no satisfactory clot-dissolving treatment.
Only about 5% of stroke patients are treated with rtPA – the only approved clot-dissolving drug – because of its short treatment time-window, suboptimal efficacy and risk of intra-cranial hemorrhage.
TSI is developing a proprietary, new-generation, clot-dissolving therapy to treat patients with acute ischemic stroke. The characteristics of TS01 address the current treatment’s shortcomings that restrict its use and limit its efficacy.